Clinical study of renal impairment in patients with propylthiouracil-induced small-vessel vasculitis and patients with primary ANCA-associated small-vessel vasculitis

Experimental and Therapeutic Medicine

Volumn 5, Issue 6, 2013, Pages 1619-1622

  Cao, Xiaozhi ^a   Lin, Weiyuan ^b  

^a FUZHOU GENERAL HOSPITAL   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Anti neutrophil cytoplasmic antibody; Propylthiouracil; Renal disease; Vasculitis

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; KIDNEY BIOPSY; KIDNEY DISEASE; MALE; PROTEINURIA; SMALL VESSEL VASCULITIS;

EID: 84876559067     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1065     Document Type: Article

References (22)

1. Erwig LP and Savage CO: ANCA-associated vasculitides: advances in pathophysiology and treatment. Neth J Med 68: 62-67, 2010.
2. Bosch X, Guilabert A, Espinosa G and Mirapeix E: Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 298: 655-669, 2007.
3. Santana AN, Woronik V, Halpern AS and Barbas CS: Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update. J Bras Pneumol 37: 809-816, 2011.
4. Bosch X, Guilabert A and Font J: Antineutrophil cytoplasmic antibodies. Lancet 368: 404-418, 2006.
5. Ghosh S, Bhattacharya M and Dhar S: Churg-strauss syndrome. Indian J Dermatol 56: 718-721, 2011.
6. Pagnoux C and Guillevin L: Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol 22: 21-28, 2010.
7. Abril A: Churg-strauss syndrome: an update. Curr Rheumatol Rep 13: 489-495, 2011.
8. Cooper DS: Antithyroid drugs. N Engl J Med 352: 905-917, 2005.
9. Azizi F: The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf 5: 107-116, 2006.
10. Radić M, Martinović Kaliterna D and Radić J: Drug-induced vasculitis: a clinical and pathological review. Neth J Med 70: 12-17, 2012.
11. Reinhold-Keller E: Diagnostics and therapy of antineutrophil cytoplasmic antibody (ANCA) associated vasculitides. Curr Pharm Des 18: 4537-4541, 2012.
12. Yu F, Chen M, Gao Y, et al: Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis 49: 607-614, 2007.
13. Sanchez AP and Ward DM: Therapeutic apheresis for renal disorders. Semin Dial 25: 119-131.
14. Stankus SJ and Johnson NT: Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure. Chest 102: 1595-1596, 1992.
15. Gao Y and Zhao MH: Review article: Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology (Carlton) 14: 33-41, 2009.
16. Chen M, Gao Y, Guo XH and Zhao MH: Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol 8: 476-483, 2012.
17. Pavone L, Grasselli C, Chierici E, et al: Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 33: 1299-1306, 2006.
18. van Timmeren MM and Heeringa P: Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr Opin Rheumatol 24: 8-14, 2012.
19. Rutgers A and Kallenberg CG: Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr Opin Rheumatol 24: 245-251, 2012.
20. Aras G: Recent aspects of vasculitis and future direction. Intern Med 50: 1869-1877, 2011.
21. Kettritz R: How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. Clin Exp Immunol 169: 220-228, 2012.
22. de Lind, van Wijngaarden RA, Hauer HA, Wolterbeek R, et al: Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17: 2264-2274, 2006.